EQH:NYSEEquitable Holdings, Inc. Analysis
Data as of 2026-06-16 - not real-time
$45.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Equitable Holdings is trading at $45.2, roughly 29% below the DCF‑derived fair value of $50.99, and its forward PE of 5.1 sits well under the industry average of 16.9, suggesting a material valuation discount. The 20‑day SMA ($41.93) and 50‑day SMA ($41.43) are both below the current price, while the 200‑day SMA ($45.09) is just under the market, indicating a tentative upside bias. Technical momentum is supportive – the MACD line is bullish at 0.55 above its signal (0.17) and the RSI at 67 signals strength without being overbought. Volume is trending down, but the stock remains above its key support of $39.42 and near the resistance of $45.44, leaving room for a short‑term breakout. Dividend policy is a bright spot, with a 2.46% yield and a recent announcement of a dividend increase, marking the seventh consecutive raise. However, the fundamentals are strained: trailing EPS is –$2.92, profit margin is –7.3%, and free cash flow is deeply negative, while debt‑to‑equity sits above 300%, raising sustainability questions. The pending Corebridge merger promises scale and potential earnings uplift, but integration risk remains. Overall, the stock offers a compelling valuation upside tempered by earnings volatility and leverage concerns.
The neutral price trend and high 30‑day volatility (≈37%) combine with a beta of 1.28 to flag heightened market sensitivity. Given the mixed signals, a cautious approach is warranted: short‑term buyers may capture the upside if the price breaks resistance, medium‑term investors should monitor merger progress and cash‑flow trends, and long‑term holders need to weigh the valuation gap against the structural earnings challenges.
The neutral price trend and high 30‑day volatility (≈37%) combine with a beta of 1.28 to flag heightened market sensitivity. Given the mixed signals, a cautious approach is warranted: short‑term buyers may capture the upside if the price breaks resistance, medium‑term investors should monitor merger progress and cash‑flow trends, and long‑term holders need to weigh the valuation gap against the structural earnings challenges.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and RSI indicating momentum
- Valuation discount of ~29% to DCF fair value
- Recent dividend increase boosting investor appeal
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Pending Corebridge merger and integration risk
- Negative earnings and free cash flow constraints
- Sustained dividend yield but high payout ratio
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Significant valuation upside if earnings improve
- High leverage and volatile earnings profile
- Sector stability in asset management balanced by regulatory exposure
Key Metrics & Analysis
Financial Health
Revenue Growth-7.60%
Profit Margin-7.26%
P/E Ratio5.1
ROE-13.52%
ROA-0.05%
Debt/Equity321.16
P/B Ratio-16.0
Op. Cash Flow$1.1B
Free Cash Flow$-9287000064
Industry P/E16.9
Technical Analysis
TrendNeutral
RSI67.2
Support$39.42
Resistance$45.44
MA 20$41.93
MA 50$41.43
MA 200$45.09
MACDBullish
VolumeDecreasing
Fear & Greed Index92.5
Valuation
Fair Value$50.99
Target Price$58.42
Upside/Downside29.24%
GradeUndervalued
TypeValue
Dividend Yield2.46%
Risk Assessment
Beta1.28
Volatility36.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.